<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, viewport-fit=cover">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="apple-mobile-web-app-status-bar-style" content="black">
    <title>Clinical Protocol: Therapeutic Transition</title>
    <style>
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol";
            line-height: 1.6;
            margin: 0;
            background-color: #000000;
            color: #EAEAEB;
            -webkit-font-smoothing: antialiased;
            text-rendering: optimizeLegibility;
        }

        .container {
            background-color: #1C1C1E;
            max-width: 100%;
            margin: 0;
            padding: env(safe-area-inset-top) env(safe-area-inset-right) env(safe-area-inset-bottom) env(safe-area-inset-left);
            padding-top: calc(15px + env(safe-area-inset-top));
            padding-bottom: calc(15px + env(safe-area-inset-bottom));
            padding-left: calc(10px + env(safe-area-inset-left));
            padding-right: calc(10px + env(safe-area-inset-right));
            box-sizing: border-box;
            min-height: 100vh;
        }

        @media (min-width: 768px) {
            .container {
                max-width: 950px; /* Increased for more content */
                margin: 0 auto;
                padding-top: 20px;
                padding-bottom: 20px;
                padding-left: 30px;
                padding-right: 30px;
                border-radius: 10px;
            }
            body {
                 padding: 15px 0;
            }
        }

        h1, h2, h3, h4 {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif;
            color: #FFFFFF;
            margin-bottom: 0.6em;
        }

        h1 {
            font-size: 2.0em;
            font-weight: 700;
            text-align: center;
            color: #FFFFFF;
            border-bottom: 2px solid #0A84FF;
            padding-bottom: 15px;
            margin-top: 0;
            margin-bottom: 25px;
        }

        h2 {
            font-size: 1.7em;
            font-weight: 600;
            margin-top: 2em;
            border-bottom: 1px solid #38383A;
            padding-bottom: 10px;
            color: #5AC8FA;
        }
        h2:first-of-type {
             margin-top: 0.8em;
        }

        h3 {
            font-size: 1.4em;
            font-weight: 600;
            color: #A2D2FF;
            margin-top: 1.8em;
        }

        h4 {
            font-size: 1.15em;
            font-weight: 600;
            color: #C7C7CC;
            margin-top: 1.3em;
        }
        h5 { /* For smaller sub-sub-headings if needed */
            font-size: 1.05em;
            font-weight: 600;
            color: #AEAEB2; /* Softer color */
            margin-top: 1.2em;
            margin-bottom: 0.4em;
        }


        p {
            margin-bottom: 1em;
            color: #D1D1D6;
            font-size: 0.95em; /* Slightly smaller default p for compactness */
        }

        ul, ol {
            margin-bottom: 1em;
            padding-left: 25px;
            font-size: 0.95em;
        }
        ul li::marker, ol li::marker {
            color: #8E8E93;
        }

        li {
            margin-bottom: 0.6em;
        }

        .formula-block, .content-block { /* .content-block for non-formula info */
            background-color: #2C2C2E;
            border: 1px solid #3A3A3C;
            border-radius: 10px;
            padding: 15px;
            margin: 20px 0;
            overflow-x: auto;
        }

        .formula-block .formula-title, .content-block .content-title {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif;
            font-size: 1.1em;
            color: #A2D2FF;
            margin-bottom: 12px;
            display: block;
            font-weight: 600;
        }

        .formula-display {
            font-size: 1.15em;
            text-align: center;
            margin-bottom: 8px;
        }

        mjx-math { color: #F2F2F7 !important; }
        mjx-container svg g[fill]:not([fill="none"]) { fill: #F2F2F7 !important; }

        .variables-list {
            list-style: none;
            padding-left: 0;
            margin-top: 12px;
            font-size: 0.9em;
        }

        .variables-list li {
            margin-bottom: 6px;
            line-height: 1.5;
            color: #AEAEB2;
        }

        .variables-list code, .inline-code {
            background-color: #3A3A3C;
            color: #F2F2F7;
            padding: 2px 6px;
            border-radius: 5px;
            font-family: "Menlo", "SFMono-Regular", Monaco, Consolas, "Liberation Mono", "Courier New", monospace;
            font-size: 0.9em;
            display: inline-block;
            vertical-align: middle;
        }
        .variables-list code mjx-math,
        .variables-list code mjx-container svg g[fill]:not([fill="none"]) {
            fill: #F2F2F7 !important;
            color: #F2F2F7 !important;
        }

        .explanation {
            margin-top: 12px;
            font-size: 0.95em;
            padding: 10px 12px;
            border-left: 3px solid #0A84FF;
            background-color: rgba(10, 132, 255, 0.08);
            border-radius: 0 8px 8px 0;
        }
        .explanation p {
            margin-bottom: 0.6em;
            color: #D1D1D6;
        }

        .note, .mcat-tip {
            font-size: 0.9em;
            padding: 10px 15px;
            margin-top: 12px;
            border-radius: 8px;
        }
        .note {
            background-color: rgba(255, 204, 0, 0.15);
            border-left: 4px solid #FFCC00;
            color: #FFEB99;
        }
        .note p { color: #FFEB99; }

        .mcat-tip {
            background-color: rgba(52, 199, 89, 0.15);
            border-left: 4px solid #34C759;
            color: #BFF2D1;
        }
        .mcat-tip p { color: #BFF2D1; }

        .disclaimer {
            background-color: rgba(255, 59, 48, 0.12);
            border-left: 4px solid #FF3B30;
            padding: 12px 18px;
            margin-bottom: 20px;
            border-radius: 8px;
            color: #FFB3AE;
            font-size: 0.9em;
        }
        .disclaimer p { color: #FFB3AE; margin-bottom: 0.5em;}

        .data-table { /* Renamed for general use */
            width: 100%;
            margin: 20px 0;
            border-collapse: separate;
            border-spacing: 0;
            font-size: 0.9em;
            border: 1px solid #38383A;
            border-radius: 8px;
            overflow: hidden;
        }
        .data-table th, .data-table td {
            border-bottom: 1px solid #38383A;
            padding: 12px 14px; 
            text-align: left;
            vertical-align: top;
        }
        .data-table td:not(:last-child),
        .data-table th:not(:last-child) {
            border-right: 1px solid #38383A;
        }
        .data-table tr:last-child td {
            border-bottom: none;
        }

        .data-table th {
            background-color: #2C2C2E;
            font-weight: 600;
            color: #A2D2FF;
        }
        .data-table td {
            color: #D1D1D6;
            background-color: #222224;
        }
        .data-table tr:nth-child(even) td {
            background-color: #252527;
        }
        .data-table td:nth-child(1) {
            font-weight: 600;
            color: #EAEAEB;
        }
        .data-table td code { /* For codes within tables */
            background-color: #3A3A3C;
            color: #F2F2F7;
            padding: 1px 4px;
            border-radius: 3px;
            font-size: 0.95em;
        }


        .section-separator {
            border: 0;
            border-top: 1px solid #48484A;
            margin: 40px 0;
        }

        /* Print styles (largely unchanged, minor adjustments if needed) */
        @media print {
            body { background-color: #fff !important; color: #000 !important; font-size: 9pt; padding: 0 !important; margin: 0 !important; } /* Smaller base font for print */
            .container { box-shadow: none !important; border: none !important; margin: 0 !important; max-width: 100% !important; padding: 10px !important; background: #fff !important; }
            h1, h2, h3, h4, h5 { color: #000 !important; }
            h1 { font-size: 20pt !important; border-bottom-color: #000 !important; }
            h2 { font-size: 15pt !important; color: #000 !important; }
            h3 { font-size: 13pt !important; color: #000 !important; }
            h4 { font-size: 11pt !important; color: #000 !important; }
            h5 { font-size: 10pt !important; color: #333 !important; }
            p, ul, ol, li { color: #000 !important; font-size: 9pt; }
            .formula-block, .content-block { background-color: #f0f0f0 !important; border: 1px solid #ccc !important; page-break-inside: avoid; color: #000 !important;}
            .formula-block .formula-title, .content-block .content-title { color: #000 !important; }
            .formula-display { color: #000 !important; }
            mjx-math { color: #000 !important; }
            mjx-container svg g[fill]:not([fill="none"]) { fill: #000 !important; }

            .variables-list li { color: #000 !important; }
            .variables-list code, .inline-code { background-color: #eee !important; border: 1px solid #ccc !important; color: #000 !important;}
            .variables-list code mjx-math, .variables-list code mjx-container svg g[fill]:not([fill="none"]) { color: #000 !important; fill: #000 !important; }
            
            .explanation { border-left-color: #aaa !important; page-break-inside: avoid; background-color: #f9f9f9 !important; color: #000 !important; }
            .explanation p { color: #000 !important; }
            .note, .mcat-tip, .disclaimer { background-color: #eee !important; border-left-color: #999 !important; color: #000 !important; page-break-inside: avoid; }
            .note p, .mcat-tip p, .disclaimer p { color: #000 !important; }

            .data-table { font-size: 8pt !important; page-break-inside: auto; color: #000 !important;}
            .data-table th, .data-table td { border: 1px solid #999 !important; color: #000 !important; background-color: #fff !important; padding: 4px 6px;}
            .data-table th { background-color: #ddd !important; color: #000 !important; }
            .data-table td:nth-child(1) { color: #000 !important; }
            .data-table td code { background-color: #eee !important; border: 1px solid #ccc !important; color: #000 !important;}
            
            a { text-decoration: none; color: #000 !important; }
            a[href^="http"]::after { content: " (" attr(href) ")"; font-size: 0.8em; }
            .section-separator { display: none !important; }
        }

    </style>
    <script>
        MathJax = {
            tex: {
                inlineMath: [['$', '$'], ['\\(', '\\)']],
                displayMath: [['$$', '$$'], ['\\[', '\\]']]
            },
            svg: {
                fontCache: 'global'
            },
            chtml: {
                fontURL: 'https://cdn.jsdelivr.net/npm/mathjax@3/es5/output/chtml/fonts/woff-v2'
            },
            options: {
                skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre', 'annotation', 'annotation-xml'],
                ignoreHtmlClass: 'tex2jax_ignore',
                processHtmlClass: 'tex2jax_process'
            }
        };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-svg.js"></script>
</head>
<body>
    <div class="container">

        <h1>Clinical Protocol: Therapeutic Transition from Risankizumab to Upadacitinib</h1>
        
        <p>This document outlines the clinical framework for evaluating and managing a patient with an inflammatory rheumatic disease for a potential therapeutic switch from risankizumab (Skyrizi) to upadacitinib (Rinvoq). The process is predicated on a structured re-evaluation of disease state, a rigorous comparative risk-benefit analysis, and a systematic protocol for initiation and monitoring.</p>

        <section id="re-evaluation">
            <h2>1.0 Focused Re-evaluation of Disease Status & Goals</h2>
            
            <h3>1.1 Assessment of Disease Activity</h3>
            <p>An objective evaluation of the patient's current disease activity is performed using standardized, validated instruments.</p>
            <ul>
                <li><strong>For Psoriatic Arthritis (PsA):</strong> Assessment includes tender and swollen joint counts, evaluation of enthesitis (e.g., Leeds Enthesitis Index), dactylitis, and skin involvement (e.g., PASI, BSA). Composite measures such as the DAPSA score or achieving Minimal Disease Activity (MDA) are key metrics.</li>
                <li><strong>For Rheumatoid Arthritis (RA):</strong> Assessment utilizes measures such as the DAS28-CRP, CDAI, or SDAI.</li>
                <li><strong>Laboratory Markers:</strong> C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are reviewed to quantify systemic inflammation.</li>
            </ul>

            <h3>1.2 Rationale for Therapeutic Modification</h3>
            <p>The specific reason(s) for considering a switch from risankizumab are formally documented. These may include:</p>
            
            <h4>Suboptimal Efficacy</h4>
            <ul>
                <li><strong>Primary Non-response:</strong> Failure to achieve a clinically meaningful improvement after a standard induction period (e.g., 16-24 weeks).</li>
                <li><strong>Secondary Loss of Response:</strong> Initial efficacy that has waned over time despite adherence to the prescribed dosing schedule (150 mg subcutaneously every 12 weeks).</li>
                <li><strong>Domain-Specific Failure:</strong> Adequate control of one disease manifestation (e.g., skin psoriasis) but persistent, unacceptable activity in another (e.g., axial disease, polyarthritis, or enthesitis).</li>
            </ul>

            <h4>Adverse Effects of Risankizumab</h4>
            <p>While generally well-tolerated, potential adverse effects prompting a change could include recurrent or severe upper respiratory infections, intolerable injection site reactions, or the development of new, paradoxical inflammatory conditions.</p>
            
            <h4>Patient Preference and Treatment Burden</h4>
            <p>Consideration is given to patient-reported outcomes, quality of life, and preference for an oral daily therapy over a quarterly subcutaneous injection. This may involve discussions about convenience, needle phobia, or the psychological burden of injectable medications.</p>
        </section>

        <hr class="section-separator">
        
        <section id="risk-benefit">
            <h2>2.0 Comparative Risk-Benefit Analysis</h2>
            <p>A critical component of the consultation is a detailed comparison of the two agents, focusing on their distinct mechanisms of action, efficacy profiles, and, most importantly, their safety profiles.</p>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Risankizumab (Skyrizi)</th>
                        <th>Upadacitinib (Rinvoq)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Mechanism of Action</strong></td>
                        <td>Selective IL-23 p19 subunit inhibitor (monoclonal antibody). Highly targeted immunomodulation.</td>
                        <td>Janus Kinase (JAK) inhibitor, primarily JAK1 (oral small molecule). Broader immunomodulation.</td>
                    </tr>
                    <tr>
                        <td><strong>Administration</strong></td>
                        <td>Subcutaneous injection (e.g., 150 mg every 12 weeks).</td>
                        <td>Oral tablet (once daily).</td>
                    </tr>
                    <tr>
                        <td><strong>Onset of Action</strong></td>
                        <td>Gradual onset of action.</td>
                        <td>Demonstrates rapid onset of action, particularly for joint symptoms.</td>
                    </tr>
                    <tr>
                        <td><strong>Serious Infections</strong></td>
                        <td>Increased risk of infections, primarily URI. Serious infections are uncommon. TB screening required.</td>
                        <td><strong>Boxed Warning:</strong> Increased risk of serious bacterial, fungal, viral, and opportunistic infections, including Tuberculosis (TB) and Herpes Zoster (shingles).</td>
                    </tr>
                    <tr>
                        <td><strong>Malignancy</strong></td>
                        <td>No established link to increased malignancy risk in current data.</td>
                        <td><strong>Boxed Warning:</strong> Increased risk of lymphomas and other malignancies, especially in current/past smokers. Non-melanoma skin cancer (NMSC) risk also increased.</td>
                    </tr>
                    <tr>
                        <td><strong>MACE (Major Adverse Cardiovascular Events)</strong></td>
                        <td>No established increased risk of MACE in current data.</td>
                        <td><strong>Boxed Warning:</strong> Increased rate of MACE (cardiovascular death, MI, stroke), particularly in patients â‰¥50 years with at least one cardiovascular risk factor.</td>
                    </tr>
                    <tr>
                        <td><strong>Thrombosis</strong></td>
                        <td>No established increased risk of VTE/arterial thrombosis in current data.</td>
                        <td><strong>Boxed Warning:</strong> Increased incidence of venous thromboembolism (VTE) and arterial thrombosis.</td>
                    </tr>
                    <tr>
                        <td><strong>Lab Abnormalities</strong></td>
                        <td>Generally minimal impact on routine labs.</td>
                        <td>Can cause dose-dependent elevations in lipids (LDL, HDL), liver transaminases (ALT/AST), and cytopenias (neutropenia, anemia). Regular monitoring required.</td>
                    </tr>
                </tbody>
            </table>
        </section>
        
        <hr class="section-separator">

        <section id="pre-initiation">
            <h2>3.0 Pre-Initiation Protocol for Upadacitinib</h2>
            <p>Should the risk-benefit analysis favor a transition, a structured pre-initiation workup is required to ensure patient safety.</p>

            <h3>3.1 Informed Consent</h3>
            <p>The patient must provide verbal and written informed consent after a thorough discussion of the rationale for the switch, the anticipated benefits, the detailed risks outlined in the upadacitinib <strong>Boxed Warning</strong>, and the mandatory monitoring requirements.</p>

            <h3>3.2 Baseline Screening and Laboratory Workup</h3>
            <div class="content-block">
                <span class="content-title">Mandatory Pre-Initiation Tests</span>
                <p>The following tests must be completed and reviewed before the first dose of upadacitinib:</p>
                <ul>
                    <li><strong>Tuberculosis Screening:</strong> Interferon-Gamma Release Assay (IGRA, e.g., QuantiFERON-TB Gold) or a Tuberculin Skin Test (TST). If positive, active TB must be ruled out and latent TB infection (LTBI) must be treated.</li>
                    <li><strong>Viral Hepatitis Serologies:</strong> Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), and hepatitis C antibody (anti-HCV).</li>
                    <li><strong>Complete Blood Count (CBC) with Differential:</strong> To establish baseline neutrophil, lymphocyte, and hemoglobin levels.</li>
                    <li><strong>Comprehensive Metabolic Panel (CMP):</strong> To assess baseline renal function and liver transaminases (ALT, AST).</li>
                    <li><strong>Fasting Lipid Panel:</strong> To establish baseline LDL-C, HDL-C, and triglycerides.</li>
                </ul>
            </div>

            <h3>3.3 Administrative Management</h3>
            <p>A comprehensive prior authorization request is submitted to the patient's insurance carrier. This documentation must clearly articulate the failure of or inadequate response to risankizumab, supported by objective clinical data, to justify the medical necessity of transitioning to a different mechanism of action.</p>
        </section>
        
        <hr class="section-separator">

        <section id="monitoring">
            <h2>4.0 Therapy Initiation and Monitoring Protocol</h2>
            
            <h3>4.1 Transition Timing</h3>
            <p>The final dose of risankizumab is noted. Upadacitinib is typically initiated at the time the next dose of risankizumab would have been due (i.e., 12 weeks after the last injection). This "washout" period is passive and generally considered safe.</p>

            <h3>4.2 Initiation and Dosing</h3>
            <p>Upadacitinib is initiated at the approved dose for the specific indication (e.g., 15 mg once daily for PsA or RA).</p>

            <h3>4.3 Post-Initiation Monitoring</h3>
            <p>A strict monitoring schedule is implemented to ensure safety and efficacy.</p>
            <ol>
                <li><strong>Initial Lab Monitoring:</strong> A CBC, CMP, and lipid panel are repeated 4 to 8 weeks after initiation, and again at 12 weeks.</li>
                <li><strong>Ongoing Lab Monitoring:</strong> Thereafter, monitoring is performed every 3 to 6 months or as clinically indicated based on results and patient risk factors.</li>
                <li><strong>Clinical Follow-up:</strong> The patient is seen in follow-up approximately 12 weeks after initiation to formally assess clinical response and screen for any adverse events.</li>
                <li><strong>Continuous Surveillance:</strong> At every visit, patients are monitored for signs and symptoms of infection, thrombosis, and malignancy. Regular skin examinations for NMSC are recommended, especially for high-risk individuals. Lipid elevations are managed according to standard cardiovascular risk guidelines, which may include initiation or adjustment of statin therapy.</li>
            </ol>
        </section>

    </div>
</body>
</html>
